TEL
AVIV, Israel, May 24, 2023
/PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB)
(Chemomab), a clinical stage biotechnology company focused on the
discovery and development of innovative therapeutics for
fibro-inflammatory diseases with high unmet need, today announced
upcoming CM-101 data presentations at major European scientific
conferences in June 2023, including
EULAR23, the European Congress of Rheumatology, and EASL
2023, the Annual Congress of the European Association for the Study
of the Liver. Further details of the presented data will be
forthcoming.
"Our poster presentations at EULAR and EASL highlight the
novelty and potential of our unique approach to fibro-inflammatory
diseases," said Dale Pfost, PhD, CEO
of Chemomab. "The presentations encompass some of our extensive
preclinical work on CCL24, whose dual activity in driving the
fibro-inflammatory vicious cycle makes it a promising target for
poorly-treated diseases including primary sclerosing cholangitis
(PSC) and systemic sclerosis (SSc). The presentations also provide
details of our clinical programs in PSC and SSc, as well as
clinical data from our Phase 2 liver fibrosis trial in NASH
patients, including some encouraging new data from recently
completed analyses. We also are pleased that our data are being
presented by respected opinion leaders who continue to be
supportive of the clinical development of CM-101, our
first-in-class therapy that targets both inflammation and
fibrosis."
EULAR23 – European Congress of
Rheumatology – Milan, Italy,
May 31-June 3, 2023
Date:
|
June 2, 2023
|
Time:
|
14:45-15:45
CEST
|
Format:
|
Poster presentation:
CCL24 serum concentration predicts both vascular and fibrotic
complications in systemic sclerosis
|
Presenter:
|
Professor Enrico De
Lorenzis, Leeds Institute of Rheumatic and Musculoskeletal
Diseases, University of Leeds, UK
|
Session:
|
Poster Hall
|
Information:
|
https://congress.eular.org/
|
|
|
EASL Congress 2023 – Vienna,
Austria, June 21-24,
2023
Date:
|
June 21 - 24,
2023
|
Time:
|
9-17:00 CEST every
day
|
Format:
|
Poster presentation:
Phase 2a study of CM-101, a CCL24 neutralizing antibody, in
patients with nonalcoholic steatohepatitis: A proof-of-concept
study
|
Presenter:
|
Professor Rifaat
Safadi, Professor in Medicine, Gastroenterology and Hepatology,
Faculty of Medicine, Hadassah University Hospital, Jerusalem,
Israel and visiting Scholar, Division of Liver Diseases, Mount
Sinai School of Medicine, New York City, USA
|
Session:
|
Poster-Late-Breaker,
LBP-28
|
Information:
|
https://congress-easl.com/
|
|
|
EASL Congress 2023 – Vienna,
Austria, June 21-24,
2023
Date:
|
June 22,
2023
|
Time:
|
9:00-18:30
CEST
|
Format:
|
Poster presentation:
Targeting CCL24 in primary sclerosing cholangitis with CM-101:
rationale and study design
|
Presenter:
|
Professor Douglas
Thorburn, Divisional Clinical Director for Liver and Digestive
Health and Professor of Hepatology , University College
London, UK
|
Session:
|
Rare Liver Diseases,
Abstract #303
|
Information:
|
https://congress-easl.com/
|
|
|
EASL Congress 2023 – Vienna,
Austria, June 21-24,
2023
Date:
|
June 23,
2023
|
Time:
|
9:00-18:00
CEST
|
Format:
|
Poster presentation:
Serum proteomics reveals association of CCL24 with key aspects
of primary sclerosing cholangitis
|
Presenter:
|
Revital Aricha, PhD,
Vice President, Translational Science, Chemomab
|
Session:
|
Immune-mediated and
cholestatic: Experimental and pathophysiology, Abstract
#2178
|
Information:
|
https://congress-easl.com/
|
|
|
In addition, Chemomab's corporate development team will be in
Boston June
5-8, 2023, participating in the BIO International
Convention's One-on-One Partnering™ event. Registered attendees
can click here to log in and schedule a meeting with
Chemomab.
About Chemomab Therapeutics
Chemomab is a clinical
stage biotechnology company discovering and developing innovative
therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique and pivotal role of the chemokine CCL24 in
promoting fibrosis and inflammation, Chemomab developed CM-101, a
monoclonal antibody designed to neutralize CCL24 activity. In
preclinical and clinical studies to date, CM-101 appears safe, with
the potential to treat multiple severe and life-threatening
fibro-inflammatory diseases. Chemomab has reported encouraging
results from a Phase 2 liver fibrosis study in NASH patients and an
investigator study in patients with severe lung injury. A Phase 2
trial in primary sclerosing cholangitis patients is ongoing and a
Phase 2 systemic sclerosis trial is expected to begin around
midyear. For more information on Chemomab, visit chemomab.com.
Forward Looking Statements
This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act. These forward-looking statements
include, among other things, statements regarding the clinical
development pathway for CM-101; the future operations of Chemomab
and its ability to successfully initiate and complete clinical
trials and achieve regulatory milestones; the nature, strategy and
focus of Chemomab; the development and commercial potential and
potential benefits of any product candidates of Chemomab; and that
the product candidates have the potential to address high unmet
needs of patients with serious fibrosis-related diseases and
conditions. Any statements contained in this communication that are
not statements of historical fact may be deemed to be
forward-looking statements. These forward-looking statements are
based upon Chemomab's current expectations. Forward-looking
statements involve risks and uncertainties. Because such statements
deal with future events and are based on Chemomab's current
expectations, they are subject to various risks and uncertainties
and actual results, performance or achievements of Chemomab could
differ materially from those described in or implied by the
statements in this presentation, including those found under the
caption "Risk Factors" and elsewhere in Chemomab's filings and
reports with the SEC. Chemomab expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Chemomab's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based, except as required by law.
Contacts:
Investors:
|
Investors & Media:
|
Irina
Koffler
|
Barbara
Lindheim
|
LifeSci Advisors,
LLC
|
Chemomab
Therapeutics
|
Phone: +1 (917)
734-7387
|
Consulting Vice
President, Investor & Public Relations
|
ir@chemomab.com
|
Strategic
Communications
|
|
barbara.lindheim@chemomab.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-participate-in-upcoming-scientific-conferences-301833186.html
SOURCE Chemomab Therapeutics, Ltd.